Currently, GC is diagnosed based on alpha-fetoprotein (AFP), cancer antigen 19-9 (CA19-9), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), and other tumor markers; however, the specificity of these markers is low, and there is a lack of effective targeted therapies [56]. Here, CEACAM5 is linked to neoplasm.